The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Open accessAbstract
Summ a r yGenome sequencing is often pivotal in the diagnosis of rare diseases, but many of these conditions lack specific treatments.We describe how molecular diagnosis of a rare, fatal neurodegenerative condition led to the rational design, testing, and manufacture of milasen, a splice-modulating antisense oligonucleotide drug tailored to a particular patient.Proof-of-concept experiments in cell lines from the patient served as the basis for launching an "N-of-1" study of milasen within 1 year after first contact with the patient.There were no serious adverse events, and treatment was associated with objective reduction in seizures (determined by electroencephalography and parental reporting).This study offers a possible template for the rapid development of patient-customized treatments.(Funded by Mila's Miracle Foundation and others.)R are diseases in aggregate affect approximately 30 million persons in the United States alone. 1 Although next-generation sequencing is revolutionizing their diagnosis, the sheer number of distinct conditions (more than 7000 [https://globalgenes .org/ rare -list]) and the limited number of patients affected by each rare disease present major challenges for drug development.This report shows a path to personalized treatment for patients with orphan diseases.It describes the identification of a novel mutation in a child with neuronal ceroid lipofuscinosis 7 (CLN7, a form of Batten's disease), a rare and fatal neurodegenerative disease.2,3 Identification of the mutation was followed by the development and clinical deployment, within 1 year, of a tailored drug to treat the patient (Fig. 1A). Clinic a l Pr esentationA 6-year-old girl presented with the insidious onset of blindness, ataxia, seizures, and developmental regression.The parents' first concerns dated back to when the girl was 3 years of age, when her right foot began to turn inward.When she was 4 years of age, her family noticed her pulling books close to her face at bedtime.At 5 years of age, she came to medical attention because of modest language and social regression, as well as increased clumsiness and stumbling.In the months before she turned 6 years of age, the progression of symptoms accelerated, and she was The authors' full names, academic degrees, and affiliations are listed in the Appendix.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,019
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D., Yu, R., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 845
Landscape of Somatic Retrotransposition in Human Cancers
Lee, E., Iskow, R., Yang, L., Gokcumen, O., Haseley, P., Luquette, L. J., Lohr, J. G., Harris, C. C., Ding, L., Wilson, R. K., et al. (2012) · Science · doi:10.1126/science.1222077 · Cited by 762
Self-citationThe Simons Simplex Collection: a resource for identification of autism genetic risk factors
Fischbach, G. D., & Lord, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.006 · Cited by 725
Lysosomal storage disorders: The cellular impact of lysosomal dysfunction
Platt, F. M., Boland, B., & van der Spoel, A. C. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201208152 · Cited by 689
Cited by
Malard, F., Wolter, A. C., Marquevielle, J., Morvan, E., Ecoutin, A., Rüdisser, S. H., Allain, F. H. T., & Campagne, S. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae201 · Cited by 1,273
RNA-based therapeutics: an overview and prospectus
Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05075-2 · Cited by 623
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
The next generation of evidence-based medicine
Subbiah, V. (2023) · Nature Medicine · doi:10.1038/s41591-022-02160-z · Cited by 544
30 years of repeat expansion disorders: What have we learned and what are the remaining challenges?
Depienne, C., & Mandel, J.-L. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.03.011 · Cited by 429
“Precision medicine (previously referred to as personalized medicine), which consists of developing a treatment entirely adapted to an individual’s disease, taking the genome and environment into account, is increasingly becoming an accessible goal in genetic disorders.(152) This concept has also been developed for sev…”
BackgroundBender, A., & Cortés-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.009 · Cited by 405
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Hammond, S. M., Aartsma‐Rus, A., Alves, S., Borgos, S. E., Buijsen, R. A. M., Collin, R. W. J., Covello, G., Denti, M. A., Desviat, L. R., Echevarría, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013243 · Cited by 388
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
Musunuru, K., Grandinette, S. A., Wang, X., Hudson, T. R., Briseno, K., Berry, A. M., Hacker, J. L., Hsu, A., Silverstein, R. A., Hille, L. T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2504747 · Cited by 368
A guide for the diagnosis of rare and undiagnosed disease: beyond the exome
Marwaha, S., Knowles, J. W., & Ashley, E. A. (2022) · Genome Medicine · doi:10.1186/s13073-022-01026-w · Cited by 359
Ahmad, F., Salem-Bekhit, M. M., Khan, F., Alshehri, S., Khan, A., Ghoneim, M. M., Wu, H.-F., Taha, E. I., & Elbagory, I. (2022) · Nanomaterials · doi:10.3390/nano12081333 · Cited by 356
Tabrizi, S. J., Estevez-Fraga, C., van Roon-Mom, W. M. C., Flower, M. D., Scahill, R. I., Wild, E. J., Muñoz-Sanjuan, I., Sampaio, C., Rosser, A. E., & Leavitt, B. R. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00121-1 · Cited by 331
The once and future gene therapy
Bulaklak, K., & Gersbach, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-19505-2 · Cited by 321
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
The powerful world of antisense oligonucleotides: From bench to bedside
Quemener, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · WIREs RNA · doi:10.1002/wrna.1594 · Cited by 280
Lauffer, M. C., van Roon-Mom, W., Aartsma-Rus, A., & Collaborative, N. =. 1. (2024) · Communications Medicine · doi:10.1038/s43856-023-00419-1 · Cited by 273
RNA therapy: rich history, various applications and unlimited future prospects
Kim, Y.-K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00757-5 · Cited by 264
RNA editing: Expanding the potential of RNA therapeutics
Booth, B. J., Nourreddine, S., Katrekar, D., Savva, Y., Bose, D., Long, T. J., Huss, D. J., & Mali, P. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.005 · Cited by 171
MicroRNAs as regulators of brain function and targets for treatment of epilepsy
Brennan, G. P., & Henshall, D. C. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0369-8 · Cited by 169
Antisense drugs make sense for neurological diseases
Bennett, C. F., Kordasiewicz, H. B., & Cleveland, D. W. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023738 · Cited by 108
Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
Nanotechnology-Based Strategies to Overcome Current Barriers in Gene Delivery
Mirón-Barroso, S., Domènech, E. B., & Trigueros, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168537 · Cited by 91
Hedrich, U. B. S., Lauxmann, S., Wolff, M., Synofzik, M., Bast, T., Binelli, A., Serratosa, J. M., Martínez-Ulloa, P., Allen, N. M., King, M. D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4957 · Cited by 87
AL Qtaish, N., Gallego, I., Villate-Beitia, I., Sainz-Ramos, M., López-Méndez, T. B., Grijalvo, S., Eritja, R., Soto-Sánchez, C., Martínez-Navarrete, G., Fernández, E., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030198 · Cited by 57
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers
Kobayashi, Y., Chhoeu, C., Li, J., Price, K. S., Kiedrowski, L. A., Hutchins, J. L., Hardin, A. I., Wei, Z., Hong, F., Bahcall, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04451-4 · Cited by 56
A single-cell map of antisense oligonucleotide activity in the brain
Mortberg, M. A., Gentile, J. E., Nadaf, N. M., Vanderburg, C., Simmons, S., Dubinsky, D., Slamin, A., Maldonado, S., Petersen, C. L., Jones, N., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad371 · Cited by 54
“Since the 2016 approval of nusinersen, an ASO modulator of pre-mRNA splicing in spinal muscular atrophy (6), 23 ASOs have entered trials for CNS disorders (1,7), with several advancing to Phase III, along with others administered on an ‘N-of-1’ basis (8–11).”
BackgroundBennett (2023) · doi:10.1097/yco.0000000000000775 · Cited by 51
“The option of precision-targeted therapeutics custom-designed for specific and rare genetic disorders (or individuals) is an area of growing interest broadly [104], that may someday yield applications for specific genetic forms of ASD.”
BackgroundAlternative strategies in cardiac preclinical research and new clinical trial formats
Kreutzer, F. P., Meinecke, A., Schmidt, K., Fiedler, J., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab075 · Cited by 36
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
DeForest, N., Kavitha, B., Hu, S., Isaac, R., Krohn, L., Wang, M., Du, X., De Arruda Saldanha, C., Gylys, J., Merli, E., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100339 · Cited by 21
Pelizaeus–Merzbacher disease: on the cusp of myelin medicine
Elitt, M. S., & Tesar, P. J. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.03.005 · Cited by 16
Yamasaki, T., Horie, T., Koyama, S., Nakao, T., Baba, O., Kimura, M., Sowa, N., Sakamoto, K., Yamazaki, K., Obika, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16017-5 · Cited by 13
Metadata
- Authors
- Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., Soucy, A., Vaze, J., Belur, N. R., Fredriksen, K., Stojkovska, I., Tsytsykova, A., Armant, M., DiDonato, R. L., Choi, J., Cornelissen, L., Pereira, L. M., Augustine, E. F., Genetti, C. A., Dies, K., Barton, B., Williams, L., Goodlett, B. D., Riley, B. L., Pasternak, A., Berry, E. R., Pflock, K. A., Chu, S., Reed, C., Tyndall, K., Agrawal, P. B., Beggs, A. H., Grant, P. E., Urion, D. K., Snyder, R. O., Waisbren, S. E., Poduri, A., Park, P. J., Patterson, A., Biffi, A., Mazzulli, J. R., Bodamer, O., Berde, C. B., & Yu, T. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1644-1652
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2979614510
- Cited by
- 827
- References
- 31
- FWCI
- 41.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.